Abstract:The introduction of immune checkpoint inhibitors represented a breakthrough treatment for metastatic melanoma, but the effect of these agents is not limited to a single cancer type. Promising results have been reported in various solid tumors, for example, lung cancer. The success of these drugs depends on the activation of tumor-infiltrating lymphocytes and primary and acquired resistance have been reported alongside a high rate of immune-related adverse events when agents targeting different immune checkpoints are given in combination. Numerous other targets have been investigated to overcome the resistance, improve the activity, and reduce the toxicity of checkpoint inhibitor therapy. Among these, the most promising is Lymphocyte-activation gene 3 (LAG-3), a transmembrane protein involved in cytokine release and inhibitory signaling in T cells. Preclinical data showed that LAG-3 is a negative regulator of both CD4+ T cell and CD8+ T cell and the activity on CD8+ T cell is independent of CD4+ activation. On the CD8+ T cell, LAG-3 activation abrogates the antigen presentation whereas on the CD4+ T cell, arrests the S phase of the cell cycle. The blockade of LAG-3 has been tested in several combination therapies, and recent clinical data showed a good safety profile and a synergistic effect with anti-PD-1, suggesting that this combination could become a standard treatment for metastatic melanoma. In this review, we report the available preclinical data and the new clinical data on LAG-3 blockade in different solid tumors, and we discuss LAG-3 as potential prognostic and predictive factor, together with possible future applications.

Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy

Lag3: From Bench to Bedside

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

LAG‐3 : recent developments in combinational therapies in cancer

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

TIGIT as an emerging immune checkpoint

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

Update in TIGIT Immune-Checkpoint Role in Cancer

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Tumor Immune Checkpoints and Their Associated Inhibitors

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation

Immune checkpoint blockade in hematological malignancies: current state and future potential

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review

Immune Checkpoints in Cancers: From Signaling to the Clinic